Editas Medicine's Turbulent Past Raises Concerns About Its Future

Editas Medicine, a clinical-stage biotech, has lost over 90% of its market value in the past five years despite a 12-month share price increase of 80%. The company's gene editing therapies are complex and expensive, making them a commercial challenge. Editas Medicine has faced setbacks, including abandoning the development of several promising candidates, raising concerns about the sustainability of its recent run and the potential for the stock to fall to zero.